{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:22:57Z","timestamp":1778070177399,"version":"3.51.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:p>\n                    Patients with liver cirrhosis and atrial fibrillation (AF) pose a therapeutic challenge due to the conflicting risks of thrombosis and bleeding. The role of direct oral anticoagulants (DOACs) in this population remains uncertain. This study aims to evaluate the impact of anticoagulation therapy on new-onset portal hypertension and related complications in cirrhotic patients with AF. A retrospective cohort study was conducted in 502 hospitalized patients with cirrhosis and AF at Beijing Ditan Hospital (2010\u20132019). Clinical data, risk scores, and liver severity indices (Child-Pugh, Model for End-Stage Liver Disease) were collected. Propensity score matching was applied to minimize confounding. Primary endpoints were new-onset portal hypertension and all-cause mortality; secondary endpoints included gastrointestinal bleeding and thromboembolic events. Among 502 patients, 50 received oral anticoagulation. Anticoagulation was associated with a significantly lower risk of new-onset portal hypertension (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and gastrointestinal bleeding (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .005) without increasing mortality (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .003). After propensity score matching (n\u2005=\u2005233), anticoagulation continued to reduce portal hypertension (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .026) and gastrointestinal bleeding (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .025), with no significant effect on mortality. Kaplan\u2013Meier analysis confirmed improved survival in the anticoagulation group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .002). In cirrhotic patients with AF, anticoagulation, particularly direct oral anticoagulants, may lower the risk of portal hypertension and gastrointestinal bleeding without increasing mortality. Prospective studies are warranted to confirm these findings and guide clinical decision-making.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047858","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:01:29Z","timestamp":1773432089000},"page":"e47858","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["DOACs reduce risk for new-onset portal hypertension in patients with cirrhosis and atrial fibrillation: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Yunjuan","family":"Su","sequence":"first","affiliation":[{"name":"Department of Cardiology, National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JingJing","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Liver Diseases, National Center for Infectious Diseases,Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8403-242X","authenticated-orcid":false,"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260506","first-page":"277","volume":"3","year":"2023","journal-title":"Cardiol Discov"},{"key":"R2-20260506","doi-asserted-by":"crossref","first-page":"e0308507","DOI":"10.1371\/journal.pone.0308507","article-title":"Differences between atrial fibrillation diagnosed before and after stroke: a large real-world cohort study.","volume":"19","author":"Chang","year":"2024","journal-title":"PLoS One"},{"key":"R3-20260506","doi-asserted-by":"crossref","first-page":"100120","DOI":"10.1016\/j.jhepr.2020.100120","article-title":"Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.","volume":"2","author":"Zermatten","year":"2020","journal-title":"JHEP Rep"},{"key":"R4-20260506","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41419-024-06892-3","article-title":"Neutrophil extracellular traps characterize caseating granulomas.","volume":"15","author":"Zlatar","year":"2024","journal-title":"Cell Death Dis"},{"key":"R5-20260506","first-page":"144","article-title":"Guidelines for the management of coagulation disorders in patients with cirrhosis, Revista de Gastroenterolog\u00eda de M\u00e9xico (English edn).","volume":"89","author":"Aiza-Haddad","year":"2024"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.","volume":"64","author":"Cerini","year":"2016","journal-title":"J Hepatol"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"e005307","DOI":"10.1161\/JAHA.116.005307","article-title":"Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"Kuo","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R9-20260506","doi-asserted-by":"crossref","first-page":"e011112","DOI":"10.1161\/JAHA.118.011112","article-title":"Effectiveness and safety of non-vitamin k antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation.","volume":"8","author":"Lee","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease.","volume":"73","author":"Lee","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"e0276","DOI":"10.1097\/HC9.0000000000000276","article-title":"Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: a randomized Phase Ib study.","volume":"7","author":"Lawitz","year":"2023","journal-title":"Hepatol Commun"},{"key":"R12-20260506","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/apt.17727","article-title":"Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension.","volume":"58","author":"Gioia","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-20260506","doi-asserted-by":"crossref","first-page":"106043","DOI":"10.1016\/j.phrs.2021.106043","article-title":"Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE-\/- mice.","volume":"175","author":"Wu","year":"2022","journal-title":"Pharmacol Res"},{"key":"R14-20260506","doi-asserted-by":"crossref","first-page":"1116177","DOI":"10.3389\/fphar.2023.1116177","article-title":"The effects and safety of anticoagulation or antiplatelet therapy following TIPS in cirrhotic patients with portal hypertension: a meta-analysis.","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R15-20260506","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jhep.2025.06.035","article-title":"Ivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.","volume":"83","author":"Puente","year":"2025","journal-title":"J Hepatology"},{"key":"R16-20260506","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.3748\/wjg.v22.i26.6036","article-title":"Umbilical cord-derived mesenchymal stem cells alleviate liver fibrosis in rats.","volume":"22","author":"Chai","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R17-20260506","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13510","article-title":"Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.","volume":"38","author":"Fortea","year":"2018","journal-title":"Liver Int"},{"key":"R18-20260506","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats by deactivating hepatic stellate cells.","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"R19-20260506","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"R20-20260506","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/jth.15829","article-title":"Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: guidance from the SSC of the ISTH.","volume":"20","author":"Torres Rojas","year":"2022","journal-title":"J Thromb Haemost"},{"key":"R21-20260506","doi-asserted-by":"crossref","first-page":"107563","DOI":"10.1016\/j.compbiomed.2023.107563","article-title":"Liver fibrosis emulationss impact of the vascular fibrotic alterations on hemodynamics.","volume":"166","author":"Torres Rojas","year":"2023","journal-title":"Comput Biol Med"},{"key":"R22-20260506","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.32169","article-title":"Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.","volume":"75","author":"Driever","year":"2022","journal-title":"Hepatology"},{"key":"R23-20260506","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13012-023-01273-4","article-title":"Implementing pharmacist-prescriber collaboration to improve evidence-based anticoagulant use: a randomized trial.","volume":"18","author":"Smith","year":"2023","journal-title":"Impl Sci"},{"key":"R24-20260506","article-title":"Update and unmet needs on the use of nonvitamin K oral anticoagulants for stroke prevention in patients with atrial fibrillation.","author":"Danilo","journal-title":"Curr Probl Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:07:11Z","timestamp":1778069231000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047858","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-10-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}